Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 162

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 7
Chunk 162
---
 shares of common stock. However, we have not confirmed the status of these shareholdings as of the date of this annual report.

According to an amendment to the Report of Substantial Shareholding (tairyo hoyu hokokusho) filed with the Director of the Kanto Local Finance Bureau on April 17, 2025, affiliates of BlackRock, Inc. beneficially owned 134,171,730 shares of our common stock, representing 8.43% of our outstanding shares of common stock. However, we have not confirmed the status of these shareholdings as of the date of this annual report.

As of March 31, 2025, there were 386 holders of record of our common stock with addresses in the U. S., whose shareholdings represented approximately 17% of our outstanding common stock on that date. One such shareholder was The Bank of New York Mellon as depositary for holders of ADSs, which held 61,745 thousand shares, or 3.91% of the total number of shares in issue, as of March 31, 2025. Because some of these shares were held by brokers or other nominees, the number of holders of record with addresses in the U. S. might not fully reflect the number of beneficial owners in the U. S.

To the extent known to us, we are not directly or indirectly owned or controlled by any other corporation, by any foreign government or by any other natural or legal person severally or jointly.

To our knowledge, there are no arrangements, which may at a subsequent date result in a change in control of us.

B. Related Party Transactions

From time to time, we enter into agreements and engage in transactions with our related parties, within the meaning of Item 7. B of Form 20-F, in the ordinary course of our business. For the fiscal year ended March 31, 2025, such transactions included, but were not limited to, R& D-related services agreements, charitable donations and equity investments transactions. The terms and conditions of our related party transactions are consistent with third-party transactions and reflect market prices. Takeda does not consider the amounts involved in these transactions to be material to its business.

C. Interests of Experts and Counsel

Not applicable.

Table of Contents

Item 8. Financial Information